Welcome to our dedicated page for Compass Pathways Plc SEC filings (Ticker: CMPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Compass Pathways plc (Nasdaq: CMPS) SEC filings page provides access to the company’s regulatory disclosures as it develops COMP360, an investigational synthetic psilocybin treatment for serious mental health conditions. As a foreign private issuer incorporated in England and Wales and listed on the Nasdaq Global Select Market, Compass reports key information to the U.S. Securities and Exchange Commission through forms such as Form 8-K, annual reports on Form 10-K, and quarterly reports on Form 10-Q.
Current reports on Form 8-K for CMPS include items on financial results, clinical milestones, and corporate governance. For example, Compass has filed 8-Ks to furnish press releases announcing financial results for periods ended June 30 and September 30, 2025, and to report board changes such as the appointments of new directors and related compensation arrangements. Other 8-K filings describe clinical developments, including achievement of the primary endpoint in the Phase 3 COMP005 trial for treatment-resistant depression.
Investors can also use this page to track periodic reports (10-K and 10-Q), which contain detailed discussions of Compass Pathways’ business, risk factors, clinical programs for treatment-resistant depression and post-traumatic stress disorder, and financial statements. These documents elaborate on topics such as research and development spending, funding needs, and the risks inherent in clinical development and regulatory review of COMP360.
In addition, this filings page can surface governance and compensation disclosures, including information about director appointments, option grants under the company’s share option and incentive plan, and indemnity arrangements, as reflected in specific 8-K items. Real-time updates from EDGAR combined with AI-powered summaries can help readers quickly understand the key points of lengthy filings, from clinical data descriptions to financial condition discussions, without reading every page of the underlying documents.
COMPASS Pathways plc reported an insider equity transaction by Chief Executive Officer and director Kabir Nath. On 02/02/2026, 16,181 Ordinary Shares were withheld by the company at $6.61 per share to cover tax obligations arising from vested restricted share units.
Following this non‑open‑market, tax‑withholding transaction, Nath directly beneficially owned 205,121 Ordinary Shares. The filing notes that the company’s Ordinary Shares may also trade as American Depositary Shares, with each ADS currently representing one Ordinary Share.
Compass Pathways entered a third amendment to its loan and security agreement with Hercules Capital, creating an amended term loan facility of up to $150 million across five tranches. The first tranche of $50 million is funded at closing, with a portion used to repay about $31.1 million of principal and PIK interest under the prior agreement. Additional tranches of up to $30 million each are tied to clinical and FDA approval milestones, plus a $20 million commercial milestone tranche and a further $20 million subject to Hercules’ investment committee.
The loans bear interest at the greater of 9.75% or 2.75% plus the Wall Street Journal prime rate, with interest-only payments until the first principal payment in the first quarter of 2029 and a scheduled maturity on January 5, 2031. The amendment includes facility and end-of-term charges, prepayment premiums, and is secured by substantially all personal property assets, along with minimum cash and performance covenants and customary default provisions.
COMPASS Pathways filed its Q3 2025 10‑Q, reporting a net loss of $137.7 million for the quarter. The loss was primarily driven by a $101.3 million fair value change of warrant liabilities, a non‑cash item tied to January 2025 financing warrants.
Operating expenses were $40.5 million, including $27.3 million in research and development and $13.2 million in general and administrative. Cash and cash equivalents were $185.9 million as of September 30, 2025. Shareholders’ equity was $37.6 million, reflecting $165.6 million of warrant liabilities on the balance sheet.
The company reported that its first Phase 3 TRD trial (COMP005) met its primary endpoint, and it plans to submit a proposal for rolling NDA submission to the FDA. It expects to disclose additional Phase 3 efficacy and safety data in 2026. The company states its cash is sufficient to fund operations into 2027. Ordinary shares outstanding were 96,017,044 as of October 30, 2025.
COMPASS Pathways plc furnished an update on November 4, 2025, announcing it issued a press release with financial results for the nine months ended September 30, 2025. The release is included as Exhibit 99.1 and the information under Item 2.02 is furnished, not filed, under the Exchange Act.
American Depositary Shares trade on the Nasdaq Global Select Market under CMPS. The report was signed by Chief Financial Officer Teri Loxam.
COMPASS Pathways plc director Jeffrey M. Jonas reported an option grant to acquire 52,000 Ordinary Shares at an exercise price of
COMPASS Pathways plc (CMPS) reported an insider ownership update. Director Jeffrey M. Jonas filed a Form 3, the initial statement of beneficial ownership, with an event date of 10/29/2025. The filing states that no securities are beneficially owned. The document was signed by Meredith Prithviraj under a power of attorney for Jeffrey M. Jonas, referencing Exhibit 24.
COMPASS Pathways (CMPS)Jeff Jonas, M.D. to its Board as a Class II director, effective October 29, 2025. He will serve on the audit and risk committee and the scientific committee. Upon joining, he will receive an option to purchase 52,000 ordinary shares (or an equivalent number of ADSs) with an exercise price set at the ADS closing price on the grant date, vesting in 36 equal monthly installments over three years.
Dr. Jonas brings leadership experience from Cure Ventures, Sage Therapeutics, ABio‑X, and multiple biotech boards. He will be eligible for annual cash retainers of $40,000 for Board service, $10,000 for audit and risk committee membership, and $6,000 for scientific committee membership. As part of a planned transition, Thomas Lönngren will retire from the Board effective December 31, 2025, and his decision was not due to any disagreement with the company.
RTW Investments, LP and Roderick Wong report shared beneficial ownership of 9,474,397 ordinary shares of COMPASS Pathways plc, representing 9.99% of the outstanding shares on a fully exercised-warrant basis. The filing states the reported amount assumes exercise of warrants to purchase 1,252,468 shares but limits exercise so the holders will not exceed 9.99% ownership. Voting and dispositive power are shared; neither reporting person claims sole voting or dispositive power. The shares are held by RTW Funds and RTW Master Fund, Ltd. is identified as having the right to receive proceeds or dividends for more than 5% of the reported shares. The filing was signed by Roderick Wong as Managing Partner of RTW Investments.
COMPASS Pathways plc Schedule 13G/A reports that TCG Crossover-affiliated funds and their managing member, Chen Yu, disclose beneficial ownership of Ordinary Shares represented by ADSs issuable upon exercise of warrants. TCG Crossover I holds 964,500 ADSs (1.0% of class) and TCG Crossover II holds 2,893,500 ADSs (2.9%), for an aggregate of 3,858,000 ADSs (3.9%) attributable to Chen Yu. The warrants may be exercisable within 60 days and are subject to an Ownership Limitation that prevents exercise to the extent it would exceed 9.99% ownership. The filers disclaim group status and state holdings are not intended to influence control.
Nantahala Capital Management, LLC and two principals report beneficial ownership of 5,934,315 American Depositary Shares of COMPASS Pathways plc, representing 6.23% of the class. The reported position includes 1,754,385 ADSs that may be acquired within sixty days through exercise of warrants, and all reported shares are held with shared voting and dispositive power rather than sole control. The filing identifies Nantahala as an investment adviser and the two individuals as control persons in respect of the shares held by Nantahala. Signatures appear for the reporting persons and a compliance officer certifies the ordinary-course nature of the holdings.
FAQ
What is the current stock price of Compass Pathways Plc (CMPS)?
What is the market cap of Compass Pathways Plc (CMPS)?
